EQS-Adhoc: MeVis Medical Solutions AG: Adjust forecast for current fiscal year

For the 2023/2024 financial year (1 October 2023 to 30 September 2024), turnover is now expected to remain stable at €17.0 million to €17.5 million (previous forecast for the 2023/2024 financial year: slight increase in turnover from €18.0 million to €18.5 million).
EBIT (earnings before interest and taxes) is expected to decline to €3.0 million to €3.5 million in the 2023/2024 financial year (1 October 2023 to 30 September 2024) (previous forecast for the 2023/2024 financial year: stability in the range of €4.5 million to €5.0 million).

The reasons for the decline in sales are an unexpected cautiousness in purchasing behaviour due to global economic challenges. In addition, the result will be strongly influenced by the development of the US dollar/euro exchange rate since the beginning of the fiscal year.

*************************************************** *************************

Contact:
Kirchhoff, Marcus / CEO

End of Inside Information

04-09-2024 CET/CEST EQS’s distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.eqs-news.com

Language:	English
Company:	MeVis Medical Solutions AG
	Caroline-Herschel-Str. 1
	28359 Bremen
	Germany
Telephone:	+49 421 224 95 0
Fax:	+49 421 224 95 999
Email address:	[email protected]
Internet:	http://www.mevis.de
ISIN code:	DE000A0LBFE4
WKN:	A0LBFE
Please mention:	Regulated market in Frankfurt (general standard); regulated unofficial market in Berlin, Düsseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1981763